5XJ3:
reference: Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., He M, Chai Y, Qi J, Zhang CWH, Tong Z, Shi Y, Yan J, Tan S, Gao GF, Oncotarget. 2017 May 19;8(40):67129-67139. doi: 10.18632/oncotarget.18004., eCollection 2017 Sep 15. PMID: 28978021

This OCA Structure page
uses Jmol, developed by the Jmol Development Team (documentation).